Compare Bristol-Myers Squibb Co (BMY) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Emerson Electric Co. — how do they compare? Bristol-Myers Squibb Co trades at $63.76 (market cap $129.94B), while Emerson Electric Co. trades at $164.08 (market cap $91.69B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | EMR | |
|---|---|---|
Market Cap | $129.94B | $91.69B |
Sector | Health | Industrials |
52-Week High | $65.89 | $164.38 |
52-Week Low | $42.60 | $123.30 |
Enterprise Value | $163.92B | $102.77B |
Dividend Yield | 3.96% | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Emerson Electric (EMR) trades at $164.56, up 3.7% on the day, reflecting strong momentum after three consecutive quarterly earnings beats. The stock exhibits a bullish technical setup, with key resistance at $168, while fundamentals show solid revenue growth and a 13.83% net income margin. Recent news highlights Q3 2026 results exceeding expectations, driven by 7% organic growth and strategic acquisitions like Glue Inc. to bolster AI capabilities in test and measurement.
Outlook remains positive with raised 2026 guidance, though valuation multiples like a P/E of 35.97 suggest premium pricing. Risks include execution challenges in integrating acquisitions and macroeconomic pressures on industrial demand. Analyst consensus favors Buy ratings with a $171.33 price target, indicating modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
